08:02 AM EDT, 06/17/2024 (MT Newswires) -- Ovid Therapeutics ( OVID ) shares slumped 64% Monday premarket after the company said that phase 3 studies conducted by Takeda evaluating Soticlestat in certain types of epilepsy missed their primary endpoints.

Kaival Brands Innovations Group ( KAVL ) shares fell 35%, paring Friday's rally.

La Rosa Holdings ( LRHC ) shares retreated 16%, shaving gains from the previous session.

Zapp Electric Vehicles Group ( ZAPP ) shares were down 11%, extending Friday's losses.

Marinus Pharmaceuticals ( MRNS ) shares dropped 8% after the company said that a phase 3 trial of intravenous ganaxolone for the treatment of refractory status epilepticus missed one of its co-primary endpoints.

Price: 1.1900, Change: -2.10, Percent Change: -63.83